About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 496193, 9 pages
http://dx.doi.org/10.1155/2013/496193
Research Article

The Prognostic Significance of CD44V6, CDH11, and -Catenin Expression in Patients with Osteosarcoma

1Department of Orthopedics, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuhan, Hubei Province 430071, China
2Department of Spine, Shandong Provincial Hospital, Jinan 250021, China

Received 29 April 2013; Revised 1 July 2013; Accepted 1 July 2013

Academic Editor: Christian Mühlfeld

Copyright © 2013 Zhouming Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology-Bone Cancer, 2012, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  2. The ESMO/European Sarcoma Network Working Group, “Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii100–vii109, 2012.
  3. C. Kong and M. F. Hansen, “Biomarkers in osteosarcoma,” Expert Opinion on Medical Diagnostics, vol. 3, no. 1, pp. 13–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. E. R. Wagner, G. Luther, G. Zhu et al., “Defective osteogenic differentiation in the development of osteosarcoma,” Sarcoma, vol. 2011, Article ID 325238, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T. S. Osborne and C. Khanna, “A review of the association between osteosarcoma metastasis and protein translation,” Journal of Comparative Pathology, vol. 146, no. 2-3, pp. 132–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Hattinger, M. Pasello, S. Ferrari, P. Picci, and M. Serra, “Emerging drugs for high-grade osteosarcoma,” Expert Opinion on Emerging Drugs, vol. 15, no. 4, pp. 615–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Nakajima, A. Patino-Garcia, S. Bruheim et al., “CDH11 expression is associated with survival in patients with osteosarcoma,” Cancer Genomics and Proteomics, vol. 5, no. 1, pp. 37–42, 2008. View at Scopus
  8. M. Kuryu, T. Ozaki, K. Nishida, M. Shibahara, A. Kawai, and H. Inoue, “Expression of CD44 variants in osteosarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 125, no. 11, pp. 646–652, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Iwaya, H. Ogawa, M. Kuroda, M. Izumi, T. Ishida, and K. Mukai, “Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis,” Clinical and Experimental Metastasis, vol. 20, no. 6, pp. 525–529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. L. Brown, L. M. Reinke, M. S. Damerow et al., “CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression,” Journal of Clinical Investigation, vol. 121, no. 3, pp. 1064–1074, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Jung, W. Gross, and M. Zöller, “CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance,” Journal of Biological Chemistry, vol. 286, no. 18, pp. 15862–15874, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. X. G. Zhang, X. F. Lu, X. M. Jiao, B. Chen, and J. X. Wu, “PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9,” Experimental and Therapeutic Medicine, vol. 4, no. 6, pp. 1005–1009, 2012.
  13. Z. J. Zhou, Z. Dai, S. L. Zhou, et al., “Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma,” International Journal of Cancer, vol. 132, no. 5, pp. 1080–1089, 2013. View at Publisher · View at Google Scholar
  14. H. Kaur, P. J. Phillips-Mason, S. M. Burden-Gulley et al., “Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo,” Molecular Cancer Research, vol. 10, no. 3, pp. 293–304, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Yagi and M. Takeichi, “Cadherin superfamily genes: functions, genomic organization, and neurologic diversity,” Genes and Development, vol. 14, no. 10, pp. 1169–1180, 2000. View at Scopus
  16. G. Berx and F. van Roy, “Involvement of members of the cadherin superfamily in cancer,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, Article ID a003129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Brieger, A. Duesterhoeft, C. Brochhausen, J. Gosepath, C. J. Kirkpatrick, and W. J. Mann, “Recurrence of pleomorphic adenoma of the parotid gland—predictive value of cadherin-11 and fascin,” APMIS, vol. 116, no. 12, pp. 1050–1057, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Thomas, “Wnts, bone and cancer,” Journal of Pathology, vol. 220, no. 1, pp. 1–4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. R. C. Haydon, A. Deyrup, A. Ishikawa et al., “Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma,” International Journal of Cancer, vol. 102, no. 4, pp. 338–342, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. W. F. Enneking, S. S. Spanier, and M. Goodman, “A system for the surgical staging of musculoskeletal sarcoma,” Clinical Orthopaedics and Related Research, vol. 153, pp. 106–120, 1980. View at Scopus
  21. B. D. Gun, B. Bahadir, S. Bektas, et al., “Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma,” Diagnostic Pathology, vol. 7, article 80, 2012. View at Publisher · View at Google Scholar
  22. Y. Cai, A. B. Mohseny, M. Karperien, P. C. W. Hogendoorn, G. Zhou, and A.-M. Cleton-Jansen, “Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma,” Journal of Pathology, vol. 220, no. 1, pp. 24–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. J. Stephens, C. D. Greenman, B. Fu et al., “Massive genomic rearrangement acquired in a single catastrophic event during cancer development,” Cell, vol. 144, no. 1, pp. 27–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Rausch, D. T. W. Jones, M. Zapatka et al., “Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations,” Cell, vol. 148, no. 1-2, pp. 59–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Saadatmand, E. M. de Kruijf, A. Sajet, et al., “Expression of cell adhesion molecules and prognosis in breast cancer,” The British Journal of Surgery, vol. 100, no. 2, pp. 252–260, 2013. View at Publisher · View at Google Scholar
  26. J. S. Park, K. M. Kim, M. H. Kim et al., “Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 expression,” Anticancer Research, vol. 29, no. 1, pp. 355–362, 2009. View at Scopus
  27. G. Zhou, D. Chiu, D. Qin, et al., “Detection and clinical significance of CD44v6 and integrin-beta1 in pancreatic cancer patients using a triplex real-time RT-PCR assay,” Applied Biochemistry and Biotechnology, vol. 167, no. 8, pp. 2257–2268, 2012. View at Publisher · View at Google Scholar
  28. A. Garouniatis, A. Zizi-Sermpetzoglou, S. Rizos, A. Kostakis, N. Nikiteas, and A. G. Papavassiliou, “FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk,” International Journal of Colorectal Disease, vol. 28, no. 1, pp. 9–18, 2013. View at Publisher · View at Google Scholar
  29. J. Shi, Z. Zhou, W. Di, and N. Li, “Correlation of CD44v6 expression with ovarian cancer progression and recurrence,” BMC Cancer, vol. 13, article 182, 2013.
  30. O. M. Omran and H. S. Ata, “CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer,” Ultrastructural Pathology, vol. 36, no. 3, pp. 145–152, 2012.
  31. A. M. Affy, S. Tate, B. Durbin-Johnson, D. M. Rocke, and T. Konia, “Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors,” International Journal of Biological Markers, vol. 26, no. 1, pp. 50–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Jijiwa, H. Demir, S. Gupta et al., “CD44V6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway,” PLoS One, vol. 6, no. 9, Article ID e24217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. W. Fan, L. Wen, Z. D. Qiang, et al., “Prognostic significance of relevant markers of cancer stem cells in colorectal cancer—a meta analysis,” Hepatogastroenterology, vol. 59, no. 117, pp. 1421–1427, 2012. View at Publisher · View at Google Scholar
  34. R. Marhaba, M. Bourouba, and M. Zöller, “CD44v6 promotes proliferation by persisting activation of MAP kinases,” Cellular Signalling, vol. 17, no. 8, pp. 961–973, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Jijiwa, H. Demir, S. Gupta et al., “CD44V6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway,” PLoS One, vol. 6, no. 9, Article ID e24217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Nakajima, K. Taniguchi, and K.-I. Mutoh, “Expression of CD44v6 as matrix-associated ectodomain in the bone development,” Journal of Veterinary Medical Science, vol. 72, no. 8, pp. 1017–1022, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Orian-Rousseau, “CD44, a therapeutic target for metastasising tumours,” European Journal of Cancer, vol. 46, no. 7, pp. 1271–1277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Yang, H.-P. Wang, X.-Y. Wang et al., “Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex pleomorphic adenoma,” Expert Opinion on Investigational Drugs, vol. 19, supplement 1, pp. S101–S108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. F. Spafford, J. Koeppe, Z. Pan, P. G. Archer, A. D. Meyers, and W. A. Franklin, “Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma,” Archives of Otolaryngology—Head and Neck Surgery, vol. 122, no. 6, pp. 627–632, 1996. View at Scopus
  40. B. Mack and O. Gires, “CD44s and CD44v6 expression in head and neck epithelia,” PLoS One, vol. 3, no. 10, Article ID e3360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. T. J. Heyse, D. Malcherczyk, R. Moll et al., “CD44: survival and metastasis in chondrosarcoma,” Osteoarthritis and Cartilage, vol. 18, no. 6, pp. 849–856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. H.-S. Kim, Y.-B. Park, J. H. Oh, J. Jeong, C. J. Kim, and S. H. Lee, “Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma,” Clinical Orthopaedics and Related Research, no. 396, pp. 184–190, 2002. View at Scopus
  43. B. D. Gun, B. Bahadir, S. Bektas, et al., “Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma,” Diagnostic Pathology, vol. 7, article 80, 2012. View at Publisher · View at Google Scholar
  44. F. J. Carmona, A. Villanueva, A. Vidal, et al., “Epigenetic disruption of cadherin-11 in human cancer metastasis,” The Journal of Pathology, vol. 228, no. 2, pp. 230–240, 2012. View at Publisher · View at Google Scholar
  45. L. Li, J. Ying, H. Li et al., “The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas,” Oncogene, vol. 31, no. 34, pp. 3901–3912, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. M. N. Marchong, C. Yurkowski, C. Ma, C. Spencer, S. Pajovic, and B. L. Gallie, “Cdh11 acts as a tumor suppressor in a murine retinoblastoma model by facilitating tumor cell death,” PLoS Genetics, vol. 6, no. 4, Article ID e1000923, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kashima, J. Kawaguchi, S. Takeshita et al., “Anomalous cadherin expression in osteosarcoma: possible relationships to metastasis and morphogenesis,” American Journal of Pathology, vol. 155, no. 5, pp. 1549–1555, 1999. View at Scopus
  48. T. Kashima, K. Nakamura, J. Kawaguchi et al., “Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo,” International Journal of Cancer, vol. 104, no. 2, pp. 147–154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, Inflammation, and Cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Warde, “Inflammation: cadherin 11: a key mediator of fibroblast inflammation,” Nature Reviews Rheumatology, vol. 7, no. 7, p. 374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. T. P. Hill, D. Später, M. M. Taketo, W. Birchmeier, and C. Hartmann, “Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes,” Developmental Cell, vol. 8, no. 5, pp. 727–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Kansara, M. Tsang, L. Kodjabachian et al., “Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice,” Journal of Clinical Investigation, vol. 119, no. 4, pp. 837–851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Bongiovanni, F. Mazzocchetti, D. Malatesta, et al., “Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma,” BMC Veterinary Research, vol. 8, article 78, 2012.
  54. F. Zhang, A. Chen, J. Chen, T. Yu, and F. Guo, “Influence of β-catenin small interfering RNA on human osteosarcoma cells,” Journal of Huazhong University of Science and Technology—Medical Science, vol. 31, no. 3, pp. 353–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. A. P. G. Guimarães, R. M. Rocha, I. W. da Cunha et al., “Prognostic impact of adenomatous polyposis coli gene expression in osteosarcoma of the extremities,” European Journal of Cancer, vol. 46, no. 18, pp. 3307–3315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. C. M. Piskun, A. Muthuswamy, M. K. Huelsmeyer, V. Thompson, and T. J. Stein, “Wnt/β-catenin expression does not correlate with serum alkaline phosphatase concentration in canine osteosarcoma patients,” PLoS One, vol. 6, no. 10, Article ID e26106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Deng, S. A. Miller, H.-Y. Wang et al., “β-catenin interacts with and inhibits NF-κB in human colon and breast cancer,” Cancer Cell, vol. 2, no. 4, pp. 323–334, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Masaki, A. Goto, M. Sugiyama, et al., “Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma,” Cancer, vol. 92, no. 10, pp. 2539–2546, 2001.